Lilly Makes Part D Pay
This article was originally published in RPM Report
Lilly is quietly acknowledging that there will be a pay off from the launch of the new Medicare prescription drug benefit, thanks to the shift of many Zyprexa patients away from the price controlled Medicaid market.
You may also be interested in...
Big Pharma's first quarter earnings reports offered the first estimates of the impact from health care reform on the industry. Wall Street was taken aback at the size of some of the hits. But not everyone is equally affected-nor will everyone be feeling the same burden when new impacts begin in 2011.
Antipsychotics in general-and Lilly's Zyprexa in particular-may be the products taking the biggest hit from health care reform. The only thing worse was the alternative.
Drug prices have lost their headline appeal. That has got to be a relief to pharma execs who have pipeline problems and patent expirations to deal with and don't need to be worried about bad publicity egging on Congress to price-control schemes. But there are new threats to drug prices brewing - and one of them is industry's old nemesis: government rebates.